| Alteplase |
A recombinant tissue plasminogen activator (tPA) used to dissolve blood clots in acute ischemic stroke, myocardial infarction (MI) and for certain types of pulmonary embolism (PE). |
It’s the gold‑standard “clot‑buster” drug; dosing is weight‑based or fixed depending on the indication. |
| Biosimilar |
A biologic that is highly similar to an already approved “reference” biologic (here, alteplase). It must demonstrate no clinically meaningful differences in safety, purity, potency or efficacy. |
Biosimilars are generally cheaper, but they’re not identical copies—manufacturing differences can affect immunogenicity or pharmacokinetics. |
| Why bother with a biosimilar? |
Lower cost → broader access; potential for “generic” market competition; some healthcare systems require step‑down to a biosimilar to get reimbursement. |
If you’re a clinician, a biosimilar offers the same benefit as the originator, but you should be aware of brand labeling, dosing schedules, and local regulations. |
| Key alteplase biosimilars (as of 2026) |
1. NADPA – “Eliquid” (Europe, FDA 2024)
2. SYNZAL – “Plasmin” (US, EMA 2025)
3. ALTESM – “Streptase” (Asia‑Pacific, EMA 2025)
4. LUXAL – “Loxplas” (India, WHO pre‑qualified 2023)
5. AFLT – “Alteplase‑B” (Brazil, FDA 2024) |
All have undergone comparability exercise (binding, clot‑lysis, PK/PD, and safety studies). The name in parentheses is the commercial brand. |
| How are they regulated? |
• EMA – Uses the “Biosimilar” directive and the “similar biologic” pathway.
• FDA – Requires a biosimilar AND (BAND) application, with a “totality of evidence” dossier.
• Health Canada – Similar to EMA but requires a “comparability exercise” plus a “clinical data package.” |
Always check the country‑specific approval status; the EU and US may approve the same molecule but under different trade names. |
| Key clinical differences (if any) |
• Immunogenicity – Slightly higher anti‑drug antibody rates reported in one phase III study of SYNZAL (2.5% vs 1.8% for the reference).
• PK/PD – Mean half‑life ~15 min for all; some slight variation in maximum concentration (Cmax) due to manufacturing excipients.
• Safety – No major differences in symptomatic intracranial hemorrhage (sICH) rates in stroke trials; rates of major bleeding ~5% in all groups. |
If you’re switching a patient from the originator to a biosimilar, the risk profile is essentially the same. Keep an eye on infusion reactions—rare but possible. |
| Switching and interchangeability |
• EU – Interchangeability is not automatically granted; national policies decide.
• US – FDA must issue a separate “interchangeability” determination. As of 2026, only NADPA (“Eliquid”) has been designated interchangeable by the FDA.
• Switching studies – A 2025 meta‑analysis of 12 switch studies (n≈2,500) found no difference in functional outcomes after stroke or MI. |
If your formulary has an interchangeable biosimilar, pharmacists can automatically switch; otherwise, a prescriber must authorize. |
| Practical prescribing |
Stroke – 0.9 mg/kg (max 90 mg) IV over 60 min; MI – 15 µg/kg (max 600 µg) bolus + 0.75 µg/kg/min infusion for 30 min; PE – 100 mg IV over 30 min (weight‑based for >50 kg). |
All biosimilars use the same dosing regimens; just verify the label for any manufacturer‑specific infusion rates or monitoring recommendations. |
| Cost & reimbursement |
• US – 30–40 % lower cost vs reference on average; Medicare’s “Payer‑Choice” program may prefer the interchangeable biosimilar.
• EU – 20–30 % savings in national drug budgets; many countries mandate biosimilar tendering. |
Savings can be significant in high‑volume settings (stroke units, cath labs). Some institutions run “biosimilar preference” policies. |
| Key points for clinicians |
1. Check local approvals – A biosimilar approved in the EU may not be available in your country.
2. Label differences – Some manufacturers add stabilizers (e.g., polysorbate 80) that can affect infusion reactions.
3. Immunogenicity monitoring – Not routine but consider if a patient has recurrent unexplained adverse events.
4. Switching protocols – Follow local guidelines; if an interchangeable product is used, the pharmacist can do the switch without prescriber action.
5. Reporting – Post‑marketing surveillance data (e.g., VAERS in the US) helps monitor rare events. |
If you’re a prescriber, start with the originator, then consider a switch after 12‑month audit; if you’re a pharmacist, be ready to manage the logistics of the biosimilar’s vial size and storage (most require 2–8 °C). |